30 closest matches · ranked by relevance
Acellular Pertussis · Tetanus · Diphtheria
Primary: Number of Subjects With Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibodies — 427; 405; 425; 412 Participants
Tetanus · Diphtheria · Pertussis
Primary: Number of Participants With Antibody Responses to Tetanus and Diphtheria Components Following Vaccination With Either Adacel® or BOOSTRIX® Vaccine — 172; 177; 196; 194…
Adolescent Immunizations · Preventive Care
Primary: Receipt of Adolescent Immunization at End of Study Period (Tdap, Menactra, HPV) — 1091; 885; 1783; 1367 participants
Adolescent HPV Vaccine · Adolescent Influenza Vaccine
Primary: Change in Percentage of Cumulative HPV Series Initiation Vaccination Rates for Adolescents 11-17 Years of Age — 13.7; 10.1; 7.8; 5.7 percent change in vaccination rates…
Pertussis · Tetanus · Diphtheria
Primary: Number of Participants Reporting A Solicited Injection Site or Systemic Reactions Within 7 Days Following Vaccination With Adacel® or Boostrix® — 273; 257; 5; 4…
Vaccine Hesitancy
Primary: Difference in the Percentage of Adolescents Who Ever Received at Least One Dose of HPV Vaccination in the Intervention Group After the Intervention Implementation…
Pertussis · Tetanus · Diphtheria
Primary: Percentage of Participants With Seroprotection Against Diphtheria and Tetanus Antigens Following Vaccination With ADACEL® — 100; 100 Percentage of Participants
Healthy
Primary: Percentage of Participants With Seroconversion in rLP2086 Specific Serum Bactericidal Assay (SBA) Titer 1 Month After Dose 2 — 0.0; 33.3; 63.6; 83.3 percentage of…
Diphtheria · Tetanus · Acellular Pertussis
Primary: Anti-diphteria (Anti-D) and Anti-tetanus (Anti-T) Antibody Concentrations — 6.784; 6.493; 18.937; 18.515 IU/mL
Meningitis · Meningococcal Meningitis · Meningococcal Infections
Primary: Percentage of Participants Achieving Vaccine Seroresponse Measured by Serum Bactericidal Assay Using Human Complement (hSBA) Against Meningococcal Serogroups A, C, Y…
Meningococcal Meningitis · Human Papillomavirus Infection · Pertussis
Primary: Percentage of Subjects With Human Serum Bactericidal Assay (hSBA) Seroresponse — 80; 82; 87; 83 Percentage of participants
Meningococcal Disease · Meningococcal Meningitis
Primary: Percentage of Subjects With an Immune Response Against Diphtheria, Tetanus and Pertussis, When Tdap is Concomitantly Administered With MenACWY-CRM Compared to Tdap Given…
Meningococcal Meningitis
Primary: Percentages of Subjects With Anti-diphtheria and Anti-tetanus Antibody Concentrations ≥ 0.1 IU/mL When Tdap is Administered Concomitantly With HPV and MenACWY-CRM…
Invasive Meningococcal Disease
Primary: Percentages of Subjects With a Seroresponse Against N.Meningitidis Serogroups A,C,W-135,Y, After Receiving Different Formulations of MenABCWY Combination Vaccine. — 90…
Diphtheria · Tetanus · Pertussis
Primary: Number of Participants With Seroprotection to Vaccine Antigens Following Vaccination With ADACEL Polio (TdcP-IPV) Vaccine. — 131; 131; 131; 131 Participants
Diphtheria · Tetanus · Pertussis
Primary: Percentage of Participants With Booster Responses for Anti-diphtheria Toxoid (Anti-D) and Anti-tetanus Toxoid (Anti-T) Antibodies — 100.0; 99.5; 98.7; 97.3 percentage of…
Immunization Status · Well Child Care Visit
Primary: Fully Vaccinated (Tdap, Menactra and 3 Doses of HPV (if Female)) — 143; 160; 100 participants — p=<0.05
Vaccine Hesitancy · Communicable Diseases in Children
Primary: Percentage of Participants With Intent to Vaccinate Adolescent Child (Tdap, MCV, HPV) — 74.3; 83.3; 97.9; 93.0 percentage of participants
Meningitis · Meningococcemia · Pertussis
Primary: Percentage of Participants With at Least a 4-fold Rise in Meningococcal Antibody Titer From Baseline (Day 0) to Day 28 Post-vaccination With Menactra® Vaccine. — 92; 94…
Vaccines · Meningococcal Vaccines
Primary: Geometric Mean Concentrations (GMC) for Diphtheria and Tetanus Antigens — 9.3; 9.8; 9.4; 10.3 IU/mL
Neoplasms, Glandular and Epithelial · Diphtheria · Tetanus
Primary: Geometric Mean Titers (GMTs) for Anti-HPV 6 at Month 7 (4 Weeks Postdose 3) — 1151.3; 1244.9 milliMerck units/mL — p=<0.001
Meningococcal Infection
Primary: Percentage of Participants in Stage 1 Achieving hSBA Titer Level Greater Than or Equal to (>=) Lower Limit of Quantitation (LLOQ) for Each of the 4 Primary Strains at…
Seasonal Influenza
Primary: Comparison of Antibody Responses of Investigational TIV to Control Vaccine in Terms of the Percentage of Subjects Achieving Seroconversion — 95; 94; 78; 87 Percentages
Hepatitis B
Primary: Serum Anti-HBs Concentration 12 IU/L or Greater — 30; 76 Participants
Tetanus · Diphtheria · Pertussis
Primary: Summary of Geometric Mean Titers of Anti-Pertussis Titers Following a Single Dose of Adacel® Vaccine — 30.1; 32.0; 232; 225 Titers (1/dilutions)
Neoplasms, Glandular and Epithelial · Diphtheria · Tetanus
Primary: Number of Subjects Who Seroconverted for Human Papillomavirus (HPV) Type 6 (HPV 6 ≥ 20 mMU/mL) by Week 4 Postdose 3 (7 Months) — 416; 417 Participants — p=<0.001
Human Papillomavirus Infection
Primary: Geometric Mean Titers (GMTs) of the Antibody Response to Each of the Human Papillomavirus (HPV) Types Contained in V503 — 2198.7; 2260.7; 1495.0; 1547.2 milli Merck…
Tetanus · Diphtheria · Pertussis
Primary: Percentage of Participants With Diphtheria and Tetanus Post-vaccination Booster Response Following Vaccination With Either SP306 or DT — 99.7; 98.3; 100; 93.8 Percentage…
Hepatitis B
Primary: Number of Subjects With Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations as Measured by ELISA Equal to or Above Cut-off Value — 266 Participants
Tuberculosis
Primary: New Infection With Mycobacterium Tuberculosis — 19; 18 Participants